These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. The comparative in-vitro activity of eight newer quinolones and nalidixic acid. King A; Phillips I J Antimicrob Chemother; 1986 Nov; 18 Suppl D():1-20. PubMed ID: 3468100 [TBL] [Abstract][Full Text] [Related]
8. [Effect ofloxacin on Haemophilus influenza, Streptococcus pneumoniae and Neisseria meningitidis. Comparison with similar molecules]. Dabernat H; Delmas C; Lareng MB Pathol Biol (Paris); 1985 May; 33(5):385-8. PubMed ID: 3162140 [TBL] [Abstract][Full Text] [Related]
9. [In vitro activity of new quinolones against Mycoplasma pathogenic to humans]. Renaudin H; Quentin C; de Barbeyrac B; Bebear C Pathol Biol (Paris); 1988 May; 36(5):496-9. PubMed ID: 3136430 [TBL] [Abstract][Full Text] [Related]
10. Respiratory infections: clinical experiences with the new quinolones. Davies BI; Maesen FP Pharm Weekbl Sci; 1987 Dec; 9 Suppl():S53-7. PubMed ID: 3438151 [TBL] [Abstract][Full Text] [Related]
11. In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. Naber KG; Sörgel F; Gutzler F; Bartosik-Wich B Infection; 1985; 13(5):219-24. PubMed ID: 2933340 [TBL] [Abstract][Full Text] [Related]
12. Enoxacin in acute exacerbations of chronic bronchitis: a comparison with amoxycillin. Prigogine T; Glupczynski Y; Carpiaux JP; Blogie M; Yourassowsky E; Schmerber JS J Antimicrob Chemother; 1988 Feb; 21 Suppl B():131-6. PubMed ID: 3129390 [TBL] [Abstract][Full Text] [Related]
13. In-vitro activity of newer quinolones against aerobic bacteria. Auckenthaler R; Michéa-Hamzehpour M; Pechère JC J Antimicrob Chemother; 1986 Apr; 17 Suppl B():29-39. PubMed ID: 2940214 [TBL] [Abstract][Full Text] [Related]
14. The use of quinolones in respiratory tract infections. Maesen FP; Davies BI; Geraedts WH; Baur C Drugs; 1987; 34 Suppl 1():74-9. PubMed ID: 3325259 [TBL] [Abstract][Full Text] [Related]
15. Clinical uses of nalidixic acid analogues: the fluoroquinolones. Høiby N Eur J Clin Microbiol; 1986 Apr; 5(2):138-40. PubMed ID: 3013628 [No Abstract] [Full Text] [Related]
16. In vitro activities of five new quinolones against 88 genital and neonatal Haemophilus isolates. Quentin R; Koubaa N; Cattier B; Gavignet M; Goudeau A Antimicrob Agents Chemother; 1988 Jan; 32(1):147-9. PubMed ID: 3258143 [TBL] [Abstract][Full Text] [Related]
17. Aztreonam in patients with acute purulent exacerbations of chronic bronchitis: failure to prevent emergence of pneumococcal infections. Davies BI; Maesen FP; Teengs JP J Antimicrob Chemother; 1985 Mar; 15(3):375-84. PubMed ID: 3922936 [TBL] [Abstract][Full Text] [Related]
18. The in-vitro activities of enoxacin and ofloxacin compared with that of ciprofloxacin. King A; Shannon K; Phillips I J Antimicrob Chemother; 1985 May; 15(5):551-8. PubMed ID: 3159712 [TBL] [Abstract][Full Text] [Related]
19. Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintenance treatment with theophylline. Wijnands WJ; Vree TB; Baars AM; van Herwaarden CL Drugs; 1987; 34 Suppl 1():159-69. PubMed ID: 3481317 [TBL] [Abstract][Full Text] [Related]
20. [Respiratory tract infections--clinical results with ofloxacin]. Shah PM; Knothe H Infection; 1986; 14 Suppl 1():S79-81. PubMed ID: 3514472 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]